Vaccines

21 Sep 2022 Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
20 Sep 2022 Pfizer Announces Positive Top-Line Results from Phase 3 Study in 20-Valent Pneumococcal Conjugate Vaccine in Infants in the European Union
16 Sep 2022 Pfizer Announces Positive Top-Line Results from Phase 3 Trial of Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
15 Sep 2022 Pfizer Initiates Phase 3 Study of mRNA-Based Influenza Vaccine
14 Sep 2022 Sabin Receives Additional $21.8 Million From BARDA to Advance Marburg Vaccine
13 Sep 2022 Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of UB-313 for Preventive Treatment of Migraine
13 Sep 2022 Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022
13 Sep 2022 Vaxxinity Initiates Rolling Submission for UB-612 COVID-19 Vaccine with MHRA (UK)
13 Sep 2022 Novavax Nuvaxovid™ COVID-19 Vaccine Granted Expanded Conditional Marketing Authorization in the European Union for Use as a Booster for Adults Aged 18 and Older
13 Sep 2022 Dynavax Announces First Participant Dosed in a Phase 2 Clinical Trial Evaluating an Adjuvanted Plague Vaccine
13 Sep 2022 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in European Union
12 Sep 2022 PDC*line Pharma presents first clinical results from Phase I/II trial with PDC*lung01 at ESMO 2022
09 Sep 2022 Genexine’s First-in-Class Therapeutic DNA Vaccine Shows Significant Potential to Extend Survival in Late-Stage Cervical Cancer
06 Sep 2022 CanSinoBIO's Convidecia Air™ Receives Approval in China
02 Sep 2022 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union
02 Sep 2022 Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
01 Sep 2022 Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
01 Sep 2022 Daiichi Sankyo Announces Initiation of Phase 3 Trial of mRNA COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
31 Aug 2022 Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
31 Aug 2022 IAVI Announces First Vaccinations at Liberia Site in Phase I Clinical Trial of Lassa Fever Vaccine Candidate
31 Aug 2022 Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older
27 Aug 2022 Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.4/BA.5 Adapted Bivalent Vaccine
25 Aug 2022 Pfizer Announces Positive Top-Line Data from Phase 3 Trial of Older Adults for its Bivalent Respiratory Syncytial Virus (RSV) Vaccine Candidate
23 Aug 2022 Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine
19 Aug 2022 CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top